After strong Q1, Q2 followed suit, attributed to gradually easing supply chain challenges and healthy progress w.r.t the productivity improvement measures. Segment-wise, D&T led the pack, followed by healthy contributions from CC and PH. More importantly, the 2023 guidance was upgraded. However, markets were spooked perhaps on the back of weaker order intake and/or concerns around China. While these risks need to be addressed (sooner or later), the focus for now should be on the firm’s turnaroun ....
